<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120233</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103072, IND143222</org_study_id>
    <secondary_id>R01AG061898</secondary_id>
    <nct_id>NCT04120233</nct_id>
  </id_info>
  <brief_title>MW151-101: First-in-human Study of MW151</brief_title>
  <official_title>A Phase 1a, Double-Blind, Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MW151 Administered Orally to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linda Van Eldik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive&#xD;
      disorders. The development program is based on nonclinical evidence that MW151 improves&#xD;
      neurocognitive outcomes in animal models of radiation-induced cognitive impairment,&#xD;
      Alzheimer's disease, and other central nervous system (CNS) disorders.&#xD;
&#xD;
      The present study will provide safety and pharmacokinetic (PK) information on single&#xD;
      ascending doses to support decisions for continued clinical development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to assess the safety and tolerability of single&#xD;
      ascending doses of MW151 when administered orally to healthy adults.&#xD;
&#xD;
      Subjects will be screened prior to inpatient admission. Subjects will be admitted to the&#xD;
      inpatient clinic on the day prior to dosing (Day -1) and will remain in the unit until&#xD;
      discharge on Day 3. A follow-up visit will be done on Day 7. A single dose of study drug or&#xD;
      placebo will be administered on Day 1. Healthy adult female subjects will be randomly&#xD;
      assigned to one of 5 dose cohorts (8 subjects each). Each subject will receive a single dose&#xD;
      of MW151 (10-160mg) or placebo under fasted conditions.&#xD;
&#xD;
      Following a review of safety and tolerability data for the first 24 hours of dosing in each&#xD;
      cohort (including reported adverse events (AEs), physical examination findings, clinical&#xD;
      laboratory results, vital signs, and electrocardiograms (ECGs), the remaining 6 subjects will&#xD;
      be randomized in a 5:1 ratio. Dosing of the remaining subjects in a cohort may proceed after&#xD;
      review of sentinel subject safety data collected during the first 24 hours of dosing and&#xD;
      determination that no stopping rules are met. The remaining subjects in each cohort will be&#xD;
      dosed sequentially, not simultaneously.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose-escalation study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Data from cohorts will be reviewed in a blinded manner.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants experiencing drug-related serious adverse events.</measure>
    <time_frame>Seven days</time_frame>
    <description>Percentage of participants experiencing drug-related serious adverse events.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Maximum Drug Concentration (Cmax)</measure>
    <time_frame>Seven days</time_frame>
    <description>Peak serum concentration of MW151.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Maximum Drug Concentration (Tmax)</measure>
    <time_frame>Seven days</time_frame>
    <description>Time required to reach the maximum serum concentration of MW151.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Drug Exposure (AUC)</measure>
    <time_frame>Seven days</time_frame>
    <description>Overall drug exposure (mg*h/L) determined by calculating the area under the curve (AUC) from a plasma drug concentration-time curve.</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug Half-Life (T1/2)</measure>
    <time_frame>Seven days</time_frame>
    <description>Time at which the concentration of MW151 is at half the maximum concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Elimination Rate Constant (Kel)</measure>
    <time_frame>Seven days</time_frame>
    <description>Fraction of MW151 eliminated per unit of time (mathematical determination).</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Drug Toxicity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 10 mg of MW151.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 20mg of MW151.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 40mg of MW151.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 80mg of MW151.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 160mg of MW151.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW151, 10mg</intervention_name>
    <description>10 mg MW151, 1 x 10mg capsule administered orally</description>
    <arm_group_label>Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW151, 20mg</intervention_name>
    <description>20 mg MW151, 1 x 20mg capsule administered orally</description>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW151, 40mg</intervention_name>
    <description>40 mg MW151, 2 x 20mg capsule administered orally</description>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW151, 80mg</intervention_name>
    <description>80 mg MW151, 1 x 80mg capsule administered orally</description>
    <arm_group_label>Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW151, 160mg</intervention_name>
    <description>160 mg MW151, 2 x 80mg capsule administered orally</description>
    <arm_group_label>Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  In good health as determined by medical history, physical exam, laboratory&#xD;
             examinations, ECG, and vital signs.&#xD;
&#xD;
          -  Weight &gt;50kg&#xD;
&#xD;
          -  BMI &lt;34 kg/m2.&#xD;
&#xD;
          -  ECG without clinically significant pathologic abnormalities and with QTcF &lt;450 ms -&#xD;
&#xD;
          -  Systolic BP ≤ 150 mmHg and diastolic BP ≤ 90 mmHg at screening&#xD;
&#xD;
          -  No suicidal ideation, as demonstrated by a score of &quot;0&quot; on the Columbia Suicide&#xD;
             Severity Rating Scale (C-SSRS).&#xD;
&#xD;
          -  Women who are neither pregnant (negative pregnancy test) nor nursing, and are either:&#xD;
             surgically sterile, postmenopausal with last natural menses greater than 24 months, or&#xD;
             premenopausal and agrees to use and acceptable form of birth control during the study&#xD;
             and for 1 month after dosing.&#xD;
&#xD;
          -  Adequate venous access for blood draws.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unstable chronic medical condition requiring interventional treatment that might&#xD;
             increase the risk to the subject or confound interpretation of safety observations.&#xD;
             Subjects who are considered stable and who have been receiving stable treatment for&#xD;
             medical condition for &gt; 3 months may be considered with approval of medical monitor.&#xD;
&#xD;
          -  Evidence of active infection requiring antibiotic therapy within 14 days prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Medical history of vasculitis or any autoimmune disease excluding seasonal allergic&#xD;
             rhinitis and childhood history of atopic dermatitis.&#xD;
&#xD;
          -  History of any treatment for cancer within the past 2 years, other than basal cell or&#xD;
             squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Seropositive for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  History of acute/chronic hepatitis B or C and/or carriers of hepatitis B&#xD;
&#xD;
          -  Clinically significant abnormalities in screening laboratory tests&#xD;
&#xD;
          -  Over-the-counter and herbal medications are prohibited within 10 days prior to study&#xD;
             dosing (with exception of calcium/vitamin D supplements and ocular medications at the&#xD;
             discretion of the Investigator). Stable doses (&gt; to 3 months of stable dose) of&#xD;
             prescription medications are allowed with the approval of the medical monitor (birth&#xD;
             control medications are allowed without medical monitor approval). Subjects should not&#xD;
             be on non-steroidal anti-inflammatory drugs or immunosuppressive drugs within 10 days&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Use of known CYP450 CYP1A2, CYP2D6 or CYP3A4 inhibitors or inducers within 14 days of&#xD;
             dosing or planned use during the study.&#xD;
&#xD;
          -  Use of an investigational drug, vaccine, device, or blood product within 3 months&#xD;
             prior to dosing in this study.&#xD;
&#xD;
          -  Any disorder that could interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs (e.g. small bowel disease, Crohn's disease, celiac disease, or&#xD;
             liver disease.)&#xD;
&#xD;
          -  Psychiatric history of current or past psychosis, bi-polar disorder, clinical&#xD;
             depression, or anxiety disorder requiring chronic medication within the past 5 years.&#xD;
&#xD;
          -  History of substance abuse including alcohol within the past 5 years.&#xD;
&#xD;
          -  Smoker.&#xD;
&#xD;
          -  Current substance or drug dependence confirmed by positive urine drug screen at&#xD;
             screening visit or Day -1 admission.&#xD;
&#xD;
          -  Current alcohol abuse confirmed by positive breathalyzer at screening visit or Day -1&#xD;
             admission.&#xD;
&#xD;
          -  History of serious head injury as determined by the site investigator or designee.&#xD;
&#xD;
          -  Chronic kidney disease (defined as the presence of any degree of proteinuria on urine&#xD;
             analysis and/or an eGFR of &lt;60 ml/min using the MDRD formula).&#xD;
&#xD;
          -  Any reason or opinion of the investigator that would prevent the subject from&#xD;
             participation in the study.&#xD;
&#xD;
          -  Inability to follow the instructions or an unwillingness to cooperate with study&#xD;
             procedures.&#xD;
&#xD;
          -  Has donated more than 500 mL of blood within the last month prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda J Van Eldik, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda J Van Eldik, PhD</last_name>
    <phone>859-257-5566</phone>
    <email>linda.vaneldik@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey T Guptill, MD</last_name>
      <phone>919-668-8445</phone>
      <email>Jeffrey.guptill@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey T Guptill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Linda Van Eldik</investigator_full_name>
    <investigator_title>Director, Sanders-Brown Center on Aging</investigator_title>
  </responsible_party>
  <keyword>cognitive disorder</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>MW151</keyword>
  <keyword>MW01-2-151SRM</keyword>
  <keyword>PK</keyword>
  <keyword>dose escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

